"Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma https://t.co/XIOqQwoLnp"

MT-601 - Marker Therap

Aug 5, 2022